Sugi Predict

Sugi Predict / Compounds / SCHEMBL190719

SCHEMBL190719

SCHEMBL190719

CCOC(=O)c1ccc(F)c(O)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 5/20 0.72
▸ CA1 P00915 5/20 0.72
▸ CA2 P00918 5/20 0.72
▸ CA7 P43166 5/20 0.72
▸ CA9 Q16790 5/20 0.72
▸ CA14 Q9ULX7 5/20 0.72
▸ HSD17B2 P37059 2/20 0.59
▸ ESR1 P03372 1/20 0.58
▸ ESR2 Q92731 1/20 0.58
▸ PTPN11 Q06124 2/20 0.52
▸ LMNA P02545 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ MAOA P21397 1/20 0.51
▸ HCRTR1 O43613 1/20 0.51
▸ MEN1 O00255 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ CASP3 P42574 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ TRPV1 Q8NER1 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184993 0.86 CA12 (0.72) CA12CA1CA2CA7CA9
SCHEMBL29823214 0.86 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL1147208 0.86 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL2175971 0.84 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL18309196 0.84 CA1 (0.74) CA12CA1CA2CA7CA9
SCHEMBL39791 0.84 CA12 (1.00) CA12CA1CA2CA7CA9
SCHEMBL29625511 0.84 CA12 (1.00) CA12CA1CA2CA7CA9
SCHEMBL3647226 0.83 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL11768705 0.83 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL27481767 0.83 CA12 (0.57) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11174271-B2 6-membered uracil isosteres CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-16 — — US disclosed
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-09-05 — — US disclosed
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 — — EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 — — EP disclosed
US-10085957-B2 Benzoic acid compounds for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2018-10-02 — — US disclosed
US-20170042844-A1 BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID PHARMA CINQ, LLC 2017-02-16 — — US disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 — — US disclosed
EP-2260028-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2014-05-07 — — EP disclosed
US-8629167-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2014-01-14 — — US disclosed
US-8629167-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2014-01-14 — — US disclosed
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 — — US disclosed
CN-1481376-A HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS ���ĵ�˹ҩ��¹����޹�˾ 2004-03-10 — — CN disclosed
US-6635641-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS, INC. 2003-10-21 — — US disclosed
EP-1349847-A1 OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS Aventis Pharma Deutschland GmbH (DE) 2003-10-08 — — EP disclosed
EP-1309567-A2 NITROGENOUS HETEROCYCLIC COMPOUNDS Millennium Pharmaceuticals, Inc. (US) 2003-05-14 — — EP disclosed
EP-1252146-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 — — EP disclosed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 — — US disclosed
WO-2002051831-A1 OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-07-04 — — WO disclosed
WO-2002016360-A2 NITROGENOUS HETEROCYCLIC COMPOUNDS COR THERAPEUTICS, INC. (US) 2002-02-28 — — WO disclosed
WO-2001053274-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10085957-B2 Benzoic acid compounds for reducing uric acid FPR1, FFAR1, GLS CA12 3091/4885CA1 591/4885CA2 369/4885
US-11174271-B2 6-membered uracil isosteres UNG, DUT, DPYD CA12 4120/4885CA1 3556/4885CA2 4284/4885
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA CA12 3865/4885CA1 3507/4885CA2 1323/4885
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA CA12 3865/4885CA1 3507/4885CA2 1323/4885
US-20170042844-A1 BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID FPR1, FFAR1, GLS CA12 3091/4885CA1 591/4885CA2 369/4885
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES UNG, DUT, DPYD CA12 4120/4885CA1 3556/4885CA2 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.